Believe it or not, the DEA does not separate anabolic/androgenic hormones. They are all Schedule III hormones to the DEA, they are not treated any differently from a regulatory standpoint. There are many physicians of different specialties prescribing things like nandrolone and oxandrolone for metabolic disease, joint pain, body composition, ED, etc. Even OBs are prescribing topical androgens like stanazolol for vaginal pain and FSD. The use of anabolics is progressing in even the most traditional settings (I get my nandrolone from a urologist at Baylor who believes its helpful to aging men with joint pain and of course it helps optimize body composition, which itself adds years to your life).This is nothing more than wishful/hopeful thinking. My prediction is that we get a carve out for Testosterone that allows it to continue to be prescribed as it is today. If you allow test you take away the transgender issue and you negate the mainstream TRT/HRT pushback. There are pretty sound straight faced arguments you can make for both of those situation.
I would be very surprised if the winstrol/anavar/deca/anadrol on demand model will be allowed to continue as is.
I wouldnt be surprised if they were the exception for this rule. If you allow test you take away the transgender issue and you negate the mainstream TRT/HRT pushback. There are pretty sound straight faced arguments you can make for both of those situation.
Anthony Roberts??? The roidstore.com and steroid.com guy?? Lol. Industry representative? Lol. Jesus if he’s the guy we’re hitching our ride to we’re doomed. That being said it’s a pretty good response.Attached is the latest comment being submitted by an industry representative. 22 pages and will be signed by multiple stakeholders
I just received an email from Defy, if you click on the buttons its pretty clear with access directly to the docket. Im sure they will appreciate any feedback as most are sending multiple emails until the cut-offI just received Defy's notification. I don't think it communicates the true nature of this issue. I doubt many will take the effort to respond as needed.
I just received an email from Defy, if you click on the buttons its pretty clear with access directly to the docket. Im sure they will appreciate any feedback as most are sending multiple emails until the cut-off
I don't know Anthony from either of those businesses, but I know Anthony the JD who is contracted across the industry as a medical-legal researcher who has contributed to successful commenting campaigns in the past. He is a contributing writer to this effort and is on Chris Bell's team as a researcher as they create the next documentary. We need to support all contributors to this effort. Even the most competitive of clinics are working together on this important issue.Anthony Roberts??? The roidstore.com and steroid.com guy?? Lol. Jesus if he’s the guy we’re hitching our ride to we’re doomed. That being said it’s a pretty good response.
it might be good to respond to them as I know they are fielding calls from patients already. There is more communication scheduled so any feedback from recipients might be appreciated. Our group is supporting multiple clinics as they build their campaigns, all of your feedback on this forum is helpful as I have been sharing this thread link.Yes, I just think it unlikely to attract enough patients to take the effort. The opening blurb:
"The DEA has proposed new rules to update the Ryan Haight Act, which could negatively affect telemedicine prescribing of non-narcotic medications in Schedules III, IV, and V. Testosterone is considered a Schedule III medication.
These rules would require in-person evaluations (physical exams), stricter record-keeping, increased coordination between physicians, and more frequent smaller refills. If approved, the update would go into effect after the current DEA waiver of the in-person exam requirement expires on May 11, 2023.
This could create unnecessary burdens for both patients and doctors, leading to limited access to treatment and increased risk of harm to patients. "
Then at the end:
"Your Defy Medical team is continuing to monitor industry changes, and we are prepared to adapt to any regulatory updates. We will communicate clearly with patients as this situation evolves."
OK then sounds like no big deal, they have me covered.
People are lazy. All of this is stated in a mild mannered tone. I am surprised there is not a bit more urgency or intensity in how they presented this.
The suggested response comment is also mild and includes very little rebuttal substance.
I wish I could say this is a conspiracy like that, but its really a handful of siloed dea attorneys on the diversion side creating rules without any understanding of how clinics operate and how patients really use telehealth. It's government waste at its finest. The DEA dosnt even understand its own Scheduling and how the medications are used in clinical settings.So other Doctors with regular practices and pharmaceutical companies decided to suppress the competition…
Where do we submit comments? Is there some kind of petition? What can actually be done about this?